97 results about "Mouse tumor" patented technology

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

The present application relates to a kind of anaphalis contorta exosome extraction method and its application.The exosome is obtained by ultra-high speed centrifugation method from fresh anaphalis contorta, particle size is 160-200 nm, Zeta potential is-21.63±1.34 mV, with double membrane structure, mainly containing protein (such as resveratrol O-methyltransferase etc.) and phospholipid, polysaccharide content is only 12.5% of anaphalis contorta fresh medicine, and does not contain traditional active ingredient anaphalis contorta glycoside.Experiments show that anaphalis contorta exosome can be targeted to enrich in colorectal tissue, significantly improve AOM / DSS induced colorectal cancer model mouse tumor microenvironment, reduce tumor number, regulate T cell and macrophage ratio, and relieve pathological damage, better than anaphalis contorta fresh medicine.The mechanism is related to protein component, not polysaccharide or small molecule component.The anaphalis contorta exosome provided in the present application has simple preparation process, high safety, and has significant anti-colorectal cancer application potential.

Provided is use of a KIF18A inhibitor in preparing a medicament for treating ovarian cancer disease. Pharmacological studies have demonstrated that compounds 1-3 can inhibit the growth of ovarian cancer heterogeneous tumors, and a high dose of the compounds can cause tumor regression in mice. Compared with AMG650, a lower drug exposure of compounds 1-3 reduces the potential drug accumulation toxicity and possesses a significant therapeutic effect on ovarian cancer with good safety.

Provided are an anti-DLL3 antibody or an antigen-binding fragment thereof, a chimeric antigen receptor and a mutant thereof, and an enhanced chimeric antigen receptor comprising a PDL1 antagonist and an mIL7 element. Further provided are a nucleic acid encoding same, an expression cassette, vector and cell comprising the nucleic acid, a preparation method, and a use for preventing, treating, detecting, or diagnosing diseases related to DLL3. In the enhanced DLL3 chimeric antigen receptor, the PDL1 antagonist and the cell membrane IL7 cytokine element play a critical role in a long-term anti-tumor process. Animal efficacy experiments have shown complete tumor regression in all mice, indicating broad application prospects in the pharmaceutical field.

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

This invention belongs to the field of cancer drug preparation technology, specifically relating to the use of compounds or their salts in the preparation of cancer therapeutic drugs. The structure of the compound is shown in Formula I. The compound shown in Formula I can significantly inhibit tumor (e.g., breast cancer) growth. Compared with the blank control group, the tumors of mice treated with the compound shown in Formula I grow more slowly, are smaller and lighter, and have a significantly longer survival period. In addition, the compound shown in Formula I can be used in combination with Anti-PD1 to synergistically enhance the tumor inhibition effect.

The invention belongs to the technical field of tumor drugs, and provides application of timosaponin A1 in treatment of colorectal cancer, and the application is that timosaponin A1 is applied to preparation of drugs for treating colorectal cancer. The inhibition effect of timosaponin A1 on mitochondrial activity in colorectal cancer cells is evaluated through in-vitro cell experiments, two mouse tumor models, multi-omics analysis and other methods; results show that timosaponin A1 can stabilize a DHRS4-LONP2-TFAM compound in vivo and in vitro, so that TFAM degradation is promoted, mitochondrial biogenesis is inhibited, tumor cell growth is inhibited, and the aim of treating colorectal cancer is achieved.

This invention belongs to the medical field and establishes a clinically relevant mouse glioblastoma treatment model, obtaining "cured" mice. When these "cured" mice were re-challenged with tumors, the tumors spontaneously regressed, and the animals achieved long-term survival. This indicates that the "cured" mice acquired immunity to the tumor, and these mice are named "cured-immune" mice. Intracranial inoculation of tumor cells into the "cured-immune" mice specifically induced a microglia subset exhibiting high expression of the purinergic receptor P2ry12 gene. High ) and immune-boosting functional characteristics, P2ry12 infusion Hi Small glial subsets significantly prolonged the survival time of glioma-bearing mice. Compared with the control group, P2ry12 in "cured-immune" (LTS) mice was significantly reduced. High Ccl12 low Differentially expressed genes in microglial cell subsets are enriched in signaling pathways that promote immune function, hence P2ry12 High Ccl12 low Microglial cell subsets have therapeutic effects on gliomas.

The invention belongs to the technical field of medicines, and generally relates to application of N-acetyl-L-tyrosine and an N-acetyltransferase strain for expressing tyrosine in preparation of tumor treatment drugs or anti-tumor immune activation drugs for elderly individuals. Researches find that N-acetyl-L-tyrosine and a tyrosine-expressing N-acetyltransferase strain can significantly inhibit mouse tumors, which shows that the mouse tumors grow slowly or the number of the mouse tumors is reduced. The N-acetyl-L-tyrosine can also regulate anti-tumor immunity, and is expressed as promoting TCF1 expression and increasing the proportion of depleted precursor T cells. In the elderly, the curative effect is particularly prominent. The results show that N-acetyl-L-tyrosine and related strains thereof can be used for tumor treatment and anti-tumor immune aging regulation.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The preparation method of the fluorescent probe (S) comprises the following steps: adding absolute ethyl alcohol into p-phenylenediamine, refluxing and dissolving the solution (solution A) while heating at 80 DEG C, dissolving salicylaldehyde into a proper amount of absolute ethyl alcohol (solution B), dropwise adding the solution B into the solution A, and stirring to obtain a mixed solution; heating reflux is kept at 80 DEG C in the whole process, stirring is continuously carried out, and after reflux is carried out for 2 hours, filtering is carried out to obtain a faint yellow solid, namely the fluorescent probe (S). The fluorescent probe can specifically recognize hydrogen sulfide (H2S) under the interference of common ions, is strong in anti-interference capability and high in sensitivity, and can be used for real-time monitoring and fluorescence imaging of endogenous H2S of cells and mouse tumors.

The invention discloses a nano drug delivery system for targeting immune cells. Comprising core nanoparticles formed by a polylactic acid-glycolic acid copolymer and used for encapsulating a therapeutic drug; the polyethylene glycol functional layer is coated on the surface of the core, so that the blood circulation time is prolonged; the targeting ligand is covalently connected to the polyethylene glycol layer, is a high-affinity ligand for specifically recognizing an immune cell surface receptor, and comprises an anti-DEC205 single-chain antibody fragment and a mannose or anti-CD3 antibody fragment. The innovation point is that the binding affinity of the targeting ligand to specific receptors on the surfaces of dendritic cells, macrophages or T cells is obviously higher than that of a conventional ligand, and efficient intracellular delivery is realized through a synergistic structure of a polylactic acid-glycolic acid copolymer-polyethylene glycol-ligand. The technical effects comprise that the in-vitro target immune cell uptake efficiency is greatly improved, the tumor tissue drug enrichment degree of a tumor-bearing mouse is multiplied compared with that of a non-targeted carrier, and the antigen presentation and T cell activation capability is remarkably enhanced.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The application belongs to the field of biological medicine, and relates to an anti-mouse integrin CD103 nanobody and application. The anti-mouse integrin CD103 nanobody comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence or a high homology sequence shown in one of SEQ ID NO:1 to SEQ ID NO:4, the amino acid sequence of CDR2 is a sequence or a high homology sequence shown in one of SEQ ID NO:5 to SEQ ID NO:8, and the amino acid sequence of CDR3 is a sequence or a high homology sequence shown in one of SEQ ID NO:9 to SEQ ID NO:12. The application relates to the anti-mouse integrin CD103 nanobody and a preparation method thereof 18 The F-CYNB nanobody probe can realize targeted imaging of myocardial fibrosis, immune imaging of mouse tumors, and prediction of the effect of tumor immunotherapy.

The present invention belongs to the field of biopharmaceutical technology, and specifically discloses a TIM-3 affinity peptide and its application. The present invention obtains TIM-3 protein affinity peptide TBS-22 (as shown in SEQ ID NO.1) by screening through phage display seven peptide library high-throughput screening technology, and obtains mutant peptide TBSM-3 (isoleucine at position 6 is mutated to histidine, as shown in SEQ ID NO.2) through later optimization and transformation. The present invention shows through in vitro cell level experiments and mouse tumor-bearing experiments that TIM-3 affinity peptide can affinity TIM-3 protein, block the interaction between TIM-3 and its ligand Galectin-9, thereby exerting anti-tumor efficacy, can be used to prepare anti-tumor drugs, has good medical application prospects, and provides a new option for tumor immunotherapy.

The invention relates to application of a pinellia ternate exosome in preparation of a medicine for resisting non-small cell lung cancer, and belongs to the technical field of Chinese herbal medicines. According to the application of the pinellia ternate exosome in preparing the non-small cell lung cancer resisting medicine, the non-small cell lung cancer resisting medicine is a tumor cell proliferation inhibitor, a tumor cell migration inhibitor or a tumor cell apoptosis accelerant. The Pinellia ternate exosome PEs is dispersed with normal saline, the effective concentration is 10-100 g / mL, the Pinellia ternate exosome PEs retains various active components of Pinellia ternate, the growth and proliferation ability and healing ability of non-small cell lung cancer cells A549 can be significantly inhibited, apoptosis of the cells A549 can be promoted, growth of tumor tissues of tumor-bearing mice can be inhibited, and the Pinellia ternate exosome PEs can be used for treating tumor-bearing mice. The important application prospect is realized in the treatment of the non-small cell lung cancer.

The invention belongs to the technical field of medicines, and particularly relates to an experimental method for treating liver cancer by using oleanolic acid. Comprising an in-vitro experiment method and an in-vivo experiment method. The in-vitro experiment method comprises the following steps: S1, cell culture; s2, cell proliferation and migration; s3, detecting cell apoptosis and a cell cycle; s4, performing immunoblotting; s5, carrying out real-time quantitative PCR; the in-vivo experiment method comprises the following steps: step 1, performing chick embryo chorioallantoic model experiment; and 2, carrying out tumor-bearing experiment, treatment and tissue sampling on the mouse. The application of the oleanolic acid in liver cancer treatment is systematically researched for the first time, it is found that the oleanolic acid has the remarkable effects of inhibiting proliferation, inducing apoptosis, resisting angiogenesis and the like on liver tumors through the synergistic effect of multiple mechanisms, the remarkable curative effect on cancer mice is achieved, and a new medicine choice is provided for liver cancer treatment.

The application discloses a kind of mouse tumor cell culture devices, including device ontology, multiple placing racks are installed in device ontology, multiple placing racks top are all set with placing groove, the inside of multiple placing racks is all provided with access mechanism, access mechanism includes multiple placing plate, the inside of multiple placing plate is all separated into multiple placing chamber by multiple partition, the inside of multiple placing chamber is provided with correction mechanism, and drive mechanism is provided in device ontology.In the application, when multiple culture dishes need to be placed in the device ontology for cultivation, the access mechanism provided in the device ontology can be used to place the multiple culture dishes one by one, without manually placing and adjusting the spacing of the multiple culture dishes repeatedly, improving the efficiency of placing the multiple culture dishes in the device ontology, reducing the time of the culture dishes in the external environment, and improving the survival rate of mouse tumor cell cultivation.

The invention discloses a Kmt2c-knocked-out CD8 + T cell, a Kmt2c-knocked-out CAR-T cell, a construction method of the Kmt2c-knocked-out CD8 + T cell and a construction method of the Kmt2c-knocked-out CAR-T cell and application of the Kmt2c Experiments prove that the infiltration number of the CD8 + T cells in tumor tissues of mice adoptively knocked out of the CD8 + T cells of the Kmt2c is obviously increased, tumor growth can be inhibited, it is indicated that the CD8 + T cells knocked out of the Kmt2c can enhance the tumor killing capacity of the CD8 + T cells, and the CD8 + T cells have the potential of preparing drugs for enhancing anti-tumor immune response; mouse tumors of CAR-T cells adoptively reducing Kmt2c expression are remarkably reduced, and the infiltration quantity of the CAR-T cells in tumor tissues is remarkably increased, so that the Kmt2c deletion type CAR-T cells can effectively inhibit tumor growth. Besides, through combined use of the Kmt2c deletion type CAR-T cell and the PD-1 antibody, it is found that the inhibition of the dryness of the Kmt2c deletion type CAR-T cell can be better improved through PD-1 antibody treatment, and the anti-tumor capacity of the Kmt2c deletion type CAR-T cell is effectively improved.

The invention provides preparation and anti-tumor application of size-controllable porphyrin photosensitive nanoparticles, the porphyrin photosensitive nanoparticles are formed by assembling a porphyrin photosensitizer and aromatic drug molecules through an anti-solvent method, and the size range of the porphyrin photosensitive nanoparticles is 10-5000 nm. The photo-thermal performance of the porphyrin photosensitive nanoparticles is obviously improved. A mouse tumor model shows that the nano-particles coated with the cell membrane can be enriched at the tumor part, the in-vivo circulation time of the nano-particles is prolonged, and the phototherapy effect is remarkable when illumination is given. The nano-drug and the treatment mode thereof have good application prospects in the aspects of drug delivery and tumor treatment.

The application discloses application of a separating enzyme inhibitor in preparation of an antitumor drug, and the separating enzyme inhibitor is toxoflavin and a derivative thereof. The compound can inhibit, at a molecular level, cleavage activity of an important proteinase, namely separating enzyme, on one subunit Scc1 of a mucin; at a cellular level, the toxoflavin derivative Walrycin B can inhibit proliferation of cancer cells such as human cervical cancer (HeLa), liver cancer (HepG2), breast cancer (MCF-7) and prostate cancer (PC3), and can arrest the cell cycle of the cancer cells at a G2 / M phase; and at an allogeneic transplantation tumor animal model, the Walrycin B can significantly inhibit growth of a mouse tumor.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

The invention relates to the technical field of supramolecular chemistry, in particular to a tetradentate pyridine ligand, a near-infrared two-region fluorescent metal cage as well as a preparation method and application of the tetradentate pyridine ligand and the near-infrared two-region fluorescent metal cage. The structural formula of the tetradentate pyridine ligand is shown in the specification, R is shown in the specification, and the element X is S or Se. The tetradentate pyridine ligand disclosed by the invention is a typical tetradentate pyridine ligand with a D-pi-A-pi-D structure and has strong near-infrared absorption capacity and efficient near-infrared two-region emission, and absorbed photon energy can be released in a fluorescent form; therefore, the metal cage prepared from the metal nano-material can be applied to in-vivo near-infrared two-region fluorescence imaging of mouse tumors. Due to the small ground state-excited state energy gap difference of the tetradentate pyridine ligand, photon energy absorbed by the metal cage prepared from the tetradentate pyridine ligand can also be released in the form of non-radiative transition, namely heat, so that the metal cage can be further applied to photo-thermal imaging and photo-thermal treatment and can play a complementary role with near-infrared two-region fluorescence imaging, and the in-vivo imaging quality is improved.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

This invention discloses a class of afterglow molecules, their preparation method, and applications, belonging to the field of biomedical optical imaging materials. By performing a Knoevenagel reaction between compound 2 (4-substituted-2,6-dicarboxyphenol) and N-substituted-2-methylbenzothiazolium bromide, inactive self-sustaining afterglow molecules QCAs are obtained. QCAs integrate reactive oxygen species generation, high-energy intermediate formation, and luminescence functions, possessing advantages such as simplified structure, low energy dissipation, and high reliability. Furthermore, an activatable self-sustaining afterglow molecule, P-QCA5, is also proposed. P-QCA5, modified with a phenylboronic acid group, can specifically respond to ONOO. ‑ It also activates the afterglow signal; leveraging its inherent low background and high signal-to-noise ratio, it successfully achieved precise imaging of mouse tumor models and Parkinson's disease (PD) models. Compared to traditional fluorescence imaging, which requires real-time excitation, afterglow imaging does not require real-time external light excitation, thus avoiding interference from tissue autofluorescence. It has a higher signal-to-noise ratio and deeper tissue detection depth, making it a promising bioimaging optical probe.

The application belongs to the field of biological medicine, and particularly relates to an information bacteriocin array against small cell lung cancer and application thereof. Amino acid sequences such as SEQ ID NO: 1-30 are provided. A drug against small cell lung cancer is also provided, which comprises a fusion protein obtained by connecting a channel domain of colicin with polypeptides with amino acid sequences such as SEQ ID NO: 1-30. Pharmacodynamics experiments prove that in each growth cycle, a mouse tumor-bearing model cannot escape the recognition and killing of the information bacteriocin array composed of thirty kinds of fusion proteins. Guinea pig model experiments prove that the continuous use of the information bacteriocin array for 30 days does not produce any toxic side effects in the animal model. The information bacteriocin array can be used as an effective drug for treating small cell lung cancer.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The invention discloses an efficient and safe CIK (cytokine-induced killer) cell preparation method and application of the CIK cell in cancer treatment, and relates to a fusion polypeptide, an anti-CD3 / CD28 / EpCAM three-function antibody and an optimized culture system. Wherein the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO. 1; the three-function antibody is prepared through technologies of phage display, homologous modeling, yeast surface screening and the like, and the affinity of the three-function antibody to EpCAM, CD3 and CD28 antigens is remarkably superior to that of a wild type. A culture system (containing 50 [mu] g / ml of the fusion polypeptide, 20 [mu] g / ml of the antibody 7B320 and 200 U / ml of IL-2200) constructed by the method can induce the proportion of CD3 + CD56 + double positive cells in the CIK cells to reach 56.2%, and the killing rate of EGFR positive A431 cells reaches 93.6% when the effect-target ratio is 40: 1. Animal experiments show that the CIK cell enables the tumor volume inhibition rate of a mouse to reach 83.2%, the median lifetime exceeds 60 days, the serum IL-6 level is only 17.6% of that of a traditional group, and a new immunotherapy strategy with high efficiency and safety is provided for EGFR positive tumors.

The application belongs to the field of organic molecule fluorescent probe, and a small molecule fluorescent probe HX is rationally designed, and the integration of diagnosis and treatment is realized by monitoring the related physical properties of tumor microenvironment and the photodynamic therapy of tumor. The tumor microenvironment of solid tumor usually has the characteristics of low pH, high viscosity, low oxygen and the like, and it is of great significance to carry out real-time monitoring and effective inhibition on tumor tissue based on the characteristic parameters of tumor site. Herein, a near-infrared fluorescent probe HX is designed, the probe does not respond to the change of surrounding viscosity in a high pH environment, however, in a low pH microenvironment of tumor, the "Donor-π-Acceptor (D-π-A)" structure thereof is opened, and sensitive viscosity response characteristics are exhibited, so that the dynamic monitoring of the tumor microenvironment is realized. In addition, through structure optimization, it is also confirmed that the probe can be used as a photosensitizer with type I reaction for photodynamic therapy of tumor tissue under hypoxic conditions. With the help of a mouse tumor model in vivo, it is confirmed that the probe HX not only has the ability to identify tumor tissue and normal tissue, but also has excellent tumor inhibition effect and good biocompatibility under hypoxic conditions, thereby providing a new technology for the diagnosis and treatment integration design of tumor diseases.

The invention provides a full-automatic mouse micro CT tumor treatment evaluation method based on a 3D time sequence. The method comprises the following steps: firstly, inputting an image of a mouse before administration and an image of the mouse after administration into a data input module together to obtain shape change query, tumor object memory and image features, and subsequently inputting the shape change query, the tumor object memory and the image features into a curative effect evaluation module; and finally, the tumor masks of the images before and after administration of the mouse and the object query stored with the tumor change information are input into a report generation module, so that a report containing the tumor treatment effect of the mouse and the recommended optimal dosage of the medicine to be used is obtained. According to the method, different models are established at the same time in different periods before and after treatment medication, the two features are fused, the optical flow model is used for learning tumor feature changes, and the detection and segmentation performance of the models is further improved.